Dayton Children's Hospital Bridges Epic Hyperdrive Migration with PortalGuard® IAM Cloud to Expand its Utilization of BIO-key Identity-Bound Biometrics

DAYTON, Ohio and WALL, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring (IBB), announced that its longstanding customer Dayton Children's Hospital will add BIO-key’s ® platform to expand its existing BIO-key biometric authentication investment as it migrates from Epic Systems’ legacy Hyperspace application to the new browser-based Hyperdrive end-user application interface. PortalGuard’s standards-based integration with Hyperdrive allows Dayton Children’s to continue enjoying BIO-key’s streamlined biometric authentication user experience for Epic security without re-enrollment or adoption of more cumbersome, shareable, and expensive multi-factor authentication solutions.

Hyperdrive is Epic’s new browser-based application platform intended to replace its client-server Citrix-based Hyperspace end-user interface. Hyperdrive’s browser-based access improves security, makes deploying and updating applications easier and allows for more choice in third-party authentication providers. All Epic customers must migrate to Hyperdrive by the November 2023 release deadline. BIO-key’s PortalGuard cloud solution fully supports Hyperdrive’s modern authentication approach through its industry-standard SAML Identity Provider (IdP) capabilities. PortalGuard’s seventeen authentication factor choices include WEB-key fingerprint authentication, the same core BIO-key biometric authentication platform that thousands of Dayton Children’s users are already enrolled in and familiar with through BIO-key’s ID Director for Epic, a direct Epic Hyperspace integration. Additionally, by moving to PortalGuard as their IdP, other hospital applications can be configured to leverage PortalGuard for biometric authentication through its support for SAML, OAUTH, and OpenID Connect standard IdP integration options.

For over a decade, BIO-key’s ID Director for Epic enhanced Hyperspace to add simple and secure biometric authentication for Epic-based hospital systems in Ohio and around the US, fully compliant with Ohio’s Board of Pharmacy and the Federal Drug Enforcement Agency (DEA) Electronic Prescribing for Controlled Substance (EPCS) authentication regulations. Since 2011, Dayton Children’s Hospital has trusted BIO-key biometric software and hardware to secure and streamline its users’ login experience for Epic, and it wanted to leverage its investment in BIO-key’s superior Epic sign-in user experience and maintain a consistent user experience to simplify the Hyperdrive migration.

"Many of BIO-key’s hospital customers use Epic, and most are already in Hyperdrive migration engagements with our technical team," said Mark Cochran, President of BIO-key – PortalGuard. "BIO-key’s unique identity-bound biometric capabilities have become a strong competitive advantage for us in healthcare because they create a long-lasting, personalized biometric authentication experience users prefer and are independent of phones, workstations, or tokens. Shared workstations are common in hospitals, yet most MFA solutions do not address them effectively, resulting in potential vulnerabilities due to token or card sharing, often committed in the name of expediency. BIO-key’s Identity-Bound Biometrics allows its hospital customers to cost-effectively leverage a phoneless, tokenless, and cardless authentication experience that users prefer because it strikes the proper balance between security and convenience."

About BIO-key International, Inc. ()

BIO-key has over two decades of expertise in providing authentication technology for thousands of organizations and millions of users and is revolutionizing authentication with biometric-centric, multi-factor identity and access management (IAM) solutions, including its PortalGuard IAM solution that provides convenient and secure access to devices, information, applications, and high-value transactions. BIO-key's patented software and hardware solutions, with industry-leading biometric capabilities, enable large-scale on-premises and cloud-based Identity-as-a-Service (IDaaS) solutions, as well as customized enterprise solutions.

BIO-key Safe Harbor Statement

All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes," and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology and identity access management industries; market acceptance of biometric products generally and our products under development; the duration and severity of the current coronavirus COVID-19 pandemic and its effect on our business operations, sales cycles, personnel, and the geographic markets in which we operate; delays in the development of products and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption see "Risk Factors'' in our Annual Report on Form 10-K for the year ended December 31, 2021 and other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, the Company undertakes no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise. Additionally, there may be other factors of which the Company is not currently aware that may affect matters discussed in forward-looking statements and may also cause actual results to differ materially from those discussed. In particular, the consequences of the coronavirus outbreak to economic conditions and the industry in general and the financial position and operating results of our Company, in particular, have been material, are changing rapidly, and cannot be predicted.

Engage with BIO-key:

Facebook – Corporate: 

LinkedIn – Corporate: 

Twitter – Corporate: Twitter – Investors: StockTwits:

Contact:

William Jones, David Collins

Catalyst IR



212-924-9800